Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of miRNAs as drug targets for detection or treatment of benign prostatic hyperplasia

A prostatic hyperplasia and drug technology, applied in the direction of DNA/RNA fragment, drug combination, recombinant DNA technology, etc., can solve the problem of less research and achieve the effect of preventing and treating benign prostatic hyperplasia

Active Publication Date: 2022-03-08
JIANGHAN UNIVERSITY
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The association between miRNA and benign prostatic hyperplasia is relatively rare

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of miRNAs as drug targets for detection or treatment of benign prostatic hyperplasia
  • Use of miRNAs as drug targets for detection or treatment of benign prostatic hyperplasia
  • Use of miRNAs as drug targets for detection or treatment of benign prostatic hyperplasia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Rat benign prostatic hyperplasia induced by testosterone propionate of embodiment 1

[0024] (1) Male Wistar rats (180-200 g) were provided by Hubei Provincial Center for Disease Control and Prevention.

[0025] (2) Rats were reared in an environment with a temperature of 22±3° C., an air humidity of 50±10%, and a day-night cycle of 12 hours / 12 hours.

[0026] (3) After one week of adaptation to the environment, the experimental animals were randomly divided into a normal control group and a benign prostatic hyperplasia model group, with 9 animals in each group. Rat models of benign prostatic hyperplasia were subjected to surgical castration (removal of the testes) and daily subcutaneous injection of 5mg / kg / d testosterone propionate (Tianjin Jinyao Pharmaceutical Co., Ltd., specification: 1mL: 25mg, batch number: 150822) for 30 consecutive days. A model of benign prostatic hyperplasia was established.

[0027] (4) After 30 days, the rats were sacrificed and the prosta...

Embodiment 2

[0028] Example 2 Testosterone Propionate Stimulates WPMY-1 and RWPE-1 Cell Proliferation

[0029] (1) Human prostate myofibroblast stromal cell line (WPMY-1 cells) and human prostate epithelial cells (RWPE-1 cells) were provided by the Chinese Academy of Sciences Stem Cell Bank.

[0030] (2) WPMY-1 cells were cultured in DMEM medium (containing 10% fetal bovine serum, 100 U / mL penicillin and 100 μg / mL streptomycin); RWPE-1 cells were cultured in keratinocyte serum-free (K-SFM ) culture medium (containing 5 ng / mL recombinant human epidermal growth factor and 0.01% gentamicin).

[0031] (3) WPMY-1 cells and RWPE-1 cells were incubated with 8 μg / mL testosterone propionate for 48 hours to stimulate the proliferation of WPMY-1 cells and RWPE-1 cells.

[0032] (4) The cells were collected, and the expression levels of hsa-miR-483-3p and hsa-miR-483-5p derived from human were detected by conventional qPCR method.

[0033] The sequence of hsa-miR-483-3p is shown in SEQ ID NO: 1, and...

Embodiment 3

[0041] Example 3 Up-regulate the expression of hsa-miR-483-3p and / or hsa-miR-483-5p on the influence of WPMY-1 cells and RWPE-1 cell proliferation

[0042] (1) Divide WPMY-1 cells and RWPE-1 cells into blank control group (group A), testosterone propionate group (group B), testosterone propionate+hsa-miR-483-3p group (group C) , testosterone propionate+hsa-miR-483-5p group (group D) and testosterone propionate+hsa-miR NC group (group E).

[0043] (2) WPMY-1 cells and RWPE-1 cells in each testosterone propionate intervention group were incubated with 8 μg / mL testosterone propionate for 48 hours, respectively.

[0044] (3) hsa-miR-483-3p intervention hsa-miR-483-3p was used to incubate for 48 hours.

[0045] (4) hsa-miR-483-5p intervention hsa-miR-483-5p was used to incubate for 48 hours.

[0046] (5) hsa-miR NC intervention hsa-miR NC was used to incubate for 48 hours.

[0047] After the cells in each group were cultured for 48 hours, the survival of the cells in each group ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of miRNA as a drug target for detecting or treating benign prostatic hyperplasia, wherein the miRNA is selected from miR-483-3p and / or miR-483-5p. The present invention finds that miR-483-3p and miR-483-5p are down-regulated in benign prostatic hyperplasia by high-throughput sequencing of the benign prostatic hyperplasia model, and further verification finds that up-regulating the expression of miR-483-3p and miR-483-5p can be Inhibit the proliferation of human prostate myofibroblast stromal cells and prostate epithelial cells, and achieve the effect of preventing and treating benign prostatic hyperplasia. That is, the present invention discovers for the first time that miR-483-3p and miR-483-5p derived from humans can be used as new molecular drug targets for detection or treatment of benign prostatic hyperplasia, which can be used to achieve the detection or drug of benign prostatic hyperplasia for screening purposes. This provides new ideas and genetic resources for the prevention and treatment of benign prostatic hyperplasia.

Description

technical field [0001] The invention belongs to the technical field of biotechnology and benign prostatic hyperplasia, and specifically relates to the application of miRNA as a drug target for detecting or treating benign prostatic hyperplasia. Background technique [0002] Benign prostatic hyperplasia (BPH) is a common disease in middle-aged and elderly men, and its incidence is on the rise and increases with age. Currently, the incidence rates of BPH in men over 50, 60 and 80 years old are about 25%, 50% and 83%, respectively. In addition, BPH is the most common cause of lower urinary tract symptoms such as dysuria and storage disorders in men. Although BPH is not a life-threatening disease in the short term, it causes extreme embarrassment and annoyance to patients' daily life, as well as huge economic pressure. With the prolongation of life expectancy and the gradual aging society in our country, the severe restriction of BPH on the quality of life of patients has attr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6883C12N15/113A61K45/00A61P13/08
CPCC12Q1/6883A61K45/00A61P13/08C12Q2600/178C12Q2600/158
Inventor 陈镜楼刘敏刘建华容楠
Owner JIANGHAN UNIVERSITY
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com